Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC plus immune checkpoint inhibitors and lenvatinib for locally advanced biliary tract cancer
ChiCTR2400091470Phase 2Recruiting
- Sponsor
- Liaoning Province Cancer Hospital
- Start
- Oct 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib and durvalumab + lenvatinib + gemcitabine + cisplatin in biliary cancer, sponsored by Liaoning Province Cancer Hospital. Primary endpoints: Objective response rate and Biliary obstruction response. Started Oct 2024; status: recruiting.
02
Drugs
lenvatinibdurvalumab + lenvatinib + gemcitabine + cisplatin
03
Conditions
biliary cancer
Beyond the preview
Go deeper on ChiCTR2400091470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091470.